The National Health Insurance Administration (NHIA) continues to enhance the hemophilia care network to ensure that patients receive tailored healthcare. The NHI currently covers over 20 medications for hemophilia, including short- and long-acting coagulation factor concentrates, bispecific antibodies, and immune toleration induction (ITI) therapy. As of March 31, 2026, the hemophilia care network serves total of 1,042 patients, comprising 866 with hemophilia A and 176 with hemophilia B.

Director General Lian-Yu Chen pointed out that in Taiwan, the treatment of hemophilia has evolved through three key development stages:

1. Transition in Treatment Models: The treatment model has transformed from on-demand treatment to prophylactic treatment, effectively reducing the risks of arthropathy and long-term disabilities.
2. Integration of Innovative Therapies: New drugs and technologies, such as long-acting coagulation factor concentrates and non-factor therapies, have been included under NHI coverage. The use of long-acting therapies and subcutaneous injections reduces injection frequency, allowing patients to maintain a near-normal lifestyle.
3. Implementation of a Case Management System: Since 2020, the NHIA has implemented a case management system for patients with hemophilia. Through a system registry, medication monitoring, and risk-sharing mechanisms, the NHIA can precisely track treatment outcomes, ensuring the efficient allocation of healthcare resources.

The NHIA included nonacog beta pegol for hemophilia B and efanesoctocog alfa for hemophilia A in the NHI coverage in 2021 and 2024, respectively. These long-acting concentrates require only weekly injections, which highly improves treatment adherence and quality of life for the patients, while reducing the financial and caregiving burdens on families.

In 2019, the NHIA introduced emicizumab, a bispecific antibody, for patients who have developed inhibitory antibodies against coagulation factor concentrates after long-term use. This medication bridges activated factor IX and factor X to restore blood clotting function. In 2023, ITI for factor VIII and factor IX was added to the NHI coverage, offering a wider variety of treatment options. In March 2026, to further enhance clinical flexibility and treatment accessibility, the NHIA expanded the use of emicizumab for patients with severe hemophilia A patients who do not have inhibitory antibodies.

The NHIA will continue to refine hemophilia treatment policies and reimbursement schemes by upholding a human-centered approach, while ensuring financial sustainability and equitable healthcare access. The ultimate goal is to provide comprehensive, stable, and high-quality healthcare, helping patients to live with ease and embrace a hopeful future.